Investigating the impact of arginine depletion with chemotherapy in aggressive prostate cancers
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
This study is looking at how lowering levels of an amino acid called arginine might make chemotherapy work better for men with aggressive prostate cancer that doesn't respond well to regular treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10932183 on NIH RePORTER |
What this research studies
This research focuses on aggressive variant prostate cancers (AVPC), which are known to be resistant to standard treatments. The study aims to explore how depleting arginine, an amino acid, can enhance the effectiveness of platinum-taxane chemotherapy in these cancers. By analyzing patient samples and conducting trials, the researchers hope to identify new combination therapies that can improve treatment outcomes for men with AVPC. The approach includes using agents that specifically target arginine metabolism, which has shown promise in preliminary studies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with aggressive variant prostate cancers who have limited treatment options.
Not a fit: Patients with non-aggressive prostate cancers or those who do not have AVPC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with aggressive variant prostate cancers.
How similar studies have performed: Preliminary studies have shown promising results with similar approaches, indicating potential for meaningful advancements in treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Aparicio, Ana — University of Tx Md Anderson Can Ctr
- Study coordinator: Aparicio, Ana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.